Business Wire.- The «Global Pulmonary Drugs Market (2021-2027) by Drug Class, Indication, Distribution Channel, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis» report has been added to ResearchAndMarkets.com’s offering.
The Global Pulmonary Drugs Market is estimated to be USD 56.9 Bn in 2021 and is expected to reach USD 69.94 Bn by 2027, growing at a CAGR of 3.5%.
The factors that are driving the market include the rising prevalence of pulmonary diseases and the growing geriatric population. The heavy investments have equally favored market growth. With the entry of innovative drugs into the markets, there is an increased scope for market growth. Government and non-government initiatives, and the availability of biosimilars, increasing tobacco smoking are fuelling the market growth.
However, factors such as low awareness about drug delivery and longer timelines are restricting the growth of the market. Expensive clinical trials and the commercialization of new drugs are some of the pulmonary drug market challenges.
The Global Pulmonary Drugs Market is segmented on the basis of Drug Class, Indication, Distribution Channel, and Geography.
Competitive Quadrant
The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Pulmonary Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using the Positioning Quadrants, the publisher’s Proprietary competitive positioning tool.
Market Dynamics
Drivers
- Rising Prevalence of Pulmonary Diseases
- Increasing Burden of Geriatric Population
- High Inclination to Tobacco Smoking
- Advantages of the Pulmonary Route as an Alternative to Oral and Parenteral Delivery Methods
Restraints
- Stringent Government Regulations for Product Approval
- Side Effects Associated with Drugs
- Less Awareness Regarding Pulmonary Drugs Delivery
Opportunities
- Heavy Investments and Research Initiatives taken by the Government into Pulmonary Drugs Therapeutics
Trends
- The Rse in the Use of Bronchodilators and Dry Powder Inhalers
- Use of Particle Engineering Techniques in Drug Formulations
Companies Mentioned
- AstraZeneca PLC
- Boehringer Ingelheim
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Grifols, S.A.
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Teva Pharmaceutical Industries Ltd.,
- MannKind Corporation
- Gilbert technologies,
- Philips Respironics,
- Novartis AG
- Sanofi
- Mylan N.V.
- Circassia
- Mallinckrodt
For more information about this report visit https://www.researchandmarkets.com/r/1bvet8